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ABSTRACT  
A library of 70 000 synthetically accessible azulene-based compounds was virtually screened 
at the OX2 receptor. Based on the results, a series of azulene derivatives was synthesized and 
the binding to and activation of both orexin receptor subtypes were assessed. Two most 
promising binders were determined to have inhibition constants in the 3–9 μM range and two 
other compounds showed weak OX2 receptor agonism. Furthermore, three compounds 
exhibited a concentration-dependent potentiation of the response to orexin-A at the OX1 but 
not the OX2 receptors. Altogether this data opens new approaches for further development of 
antagonists, agonists, and potentiators of orexin response based on the azulene scaffold. 
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1 INTRODUCTION 
The orexin (hypocretin) system, comprising the two G protein-coupled orexin receptors OX1 
and OX2 and the agonistic neuropeptides orexin-A and orexin-B, plays a key role in sleep-wake 
regulation.[1–3] In addition to arousal, the orexin system has been reported to affect 
metabolism, nociception, addiction, and stress response.[4] The orexin system has primarily 
been targeted in sleep-promoting pharmacotherapies, resulting in a large number of orexin 
receptor antagonists developed for insomnia.[3,5] Orexin receptor agonists, however, have 
received less attention, and only a few small molecular agonists have been reported.[6–10] In 
the CNS, orexin receptor agonists might prove useful in the treatment of daytime sleepiness, 
especially in narcolepsy.[11] Activating orexin receptors in periphery would have other 
therapeutic indications, such as cancer.[12] Small molecular potentiators that enhance the 
effects of endogenous orexin-A have also been reported.[13] These potentiators would have 
application as orexin receptor activation therapies when production of the endogenous peptides 
is not fully terminated. 
In our efforts to target orexin receptors, we decided to explore azulene-based compounds 
postulating that the lipophilic azulene ring could be integrated into a peptide mimetic of the 
amphipatic α-helical C-terminus of orexin-A.[21,22] A supporting observation was that 
multiple aromatic rings are found in known orexin receptor ligands, usually as biaryls or fused 
bicyclic aryls.[3] Azulene is an interesting scaffold in medicinal chemistry as it resembles 
several other bicyclic aromatics that are frequently found in drugs. Azulene, a structural isomer 
of naphthalene, is a bicyclic nonbenzenoid aromatic hydrocarbon having a dipole moment due 
to the electron-rich five-membered ring and electron-deficient seven-membered ring.[14] 
Therefore, it bears resemblance also to indole. In medicinal chemistry, azulene is an unexplored 
scaffold; only one azulene-based drug, the antiulcer agent egualen sodium, is currently on the 
market.[15] In addition, there are a few other published examples of azulenes with application 
as anticancer [16–18] and antidiabetic [19] agents and in erectile dysfunction.[20] 
The study was initiated by developing general synthetic protocols to access 1,3,6-
trisubstituted azulenes.[21,22] These positions are on different edges of the azulene ring and 
reach a large space around the central scaffold. In addition, the positions 1 and 3 are the most 
reactive sites on the azulene ring, and substituting these positions is therefore beneficial for the 
stability of the end products. Furthermore, the substitution at the 6-position yields symmetrical 
synthesis intermediates. This facilitates the further substitution of 1- and 3-positions, namely 
by avoiding selectivity issues during the synthesis. As the developed synthetic routes make 
thousands of compounds accessible, we employed a docking-based virtual screening to 
prioritize the compounds to be synthesized. 
 
 
2 RESULTS AND DISCUSSION 
2.1 Selecting compounds for synthesis. To prioritize compounds for synthesis, we first 
constructed a virtual library of di- and trisubstituted azulenes using the combinatorial database 
   
 
 3 
building tool of Schrödinger Maestro 2015v3.[23] We selected a pool of substituents presenting 
diverse physicochemical properties and size; we also included substituents that are found in 
already published agonists/antagonists of the orexin receptors. These substituents vary in their 
hydrogen-bonding properties, size, aromaticity, and the lengths of linkers between the 
substituents and the azulene scaffold. The substituents placed in the compounds actually 
synthesized was driven in part by our expectation that a particular combination would be 
synthetically accessible. The initial pool of substituents at the 1- and 3-positions was composed 
of the same 63 functional groups; the whole pool was used at the 1-position, while at the 3-
position, after considering the viability of the resulting combinations, we used 46 substituents 
(of which 45 are directly a subset of the initial pool; Supporting Information Figure S1). At the 
6-position the initial pool was composed for one half of the subset of substituents used for 1-
position and for the other half of a new set of polar/charged substituents. As a result, a virtual 
library containing 70 038 azulene-based compounds of molecular weight under 500 g/mol was 
constructed.  
We then docked this virtual library to the three-dimensional structure of the OX2 receptor 
[24] using the software Glide from the Schrödinger Maestro 2015v3 package.[23] The docking 
was conducted under the assumption of binding at the site of the co-crystallized antagonist. A 
shortlist of compounds was constructed among the 200 top-scoring docking poses that 
interacted with Gln1343.32 (for nomenclature see references [25,26]) and preferably also with 
Tyr3176.48. These interactions are present in the used OX2 crystal structure,[24] and suggested 
to take place upon binding of the endogenous peptide orexin-A.[27] 
The favorable interactions with Gln1343.32 and Tyr3176.48 were frequently formed by 
compounds with unsubstituted or 4-trifluoromethyl-substituted benzoyl groups at the 1-
position, hydrogen atoms or unsubstituted and 4-methoxy-substituted benzoyl groups at the 3-
position, and amide or carboxyl groups at the 6-position. We thus prioritized compounds with 
these substituents for synthesis. The functional groups outlined to make favorable interactions 
with Gln1343.32 and Tyr3176.48 are among the preferred substituents but not necessarily ranked 
first; when we studied the substituent distribution in the top-scoring 5% of the docked database 
(7200 poses; Supporting Information Figures S2 and S3), the benzoyl and 4-
(trifluoromethyl)benzoyl groups ranked 6th and 15th in the 1-position, hydrogen atom and 
benzoyl group ranked 7th and 33rd in the 3-position,  and primary carboxamide, and the 
corresponding carboxyl group ranked 1st and 6th in the 6-position. This is explainable by the 
compounds being assessed as a whole by the docking program. In total, we decided to 
synthesize 16 compounds from the shortlist, and to test them together with eight previously 
synthesized compounds [22] and seven synthetic intermediates. 
 
2.2 Synthesis. We used 6-methylazulene (1) as the starting material to synthesize the 
designed compounds employing formylation, iodination, Suzuki cross-coupling and the 
modified Vilsmeier–Haack reactions in the functionalization of the five-membered ring of 
azulene, as described before.[21] Additionally, we have previously demonstrated conversion 
of the methyl group at the 6-position to other functionalities, either via a formyl group, or via 
a methyl anion. This methodology was developed further in this study as described below. 
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We investigated oxidation of 6-formylazulene (2) to obtain the ester 4. Since our attempts to 
synthesize 4 directly from 2 with a method originally developed for benzaldehydes failed,[28] 
we oxidized 2 with Oxone to give 6-carboxyazulene (3) in 48% yield (Scheme 1). The reaction 
did not go to completion as 32% of the starting material was recovered. Extension of the 
reaction time did not improve the yield, although the starting material was now consumed 
almost completely. Nevertheless, the ester 4 was obtained after treating 3 with iodomethane in 
the presence of base. 
 
Scheme 1. Synthesis of designed azulene-based compounds. Reagents and conditions: (a) see 
ref.[21] (b) Oxone, DMF, rt, 3 h, 48%; (c) K2CO3, iodomethane, DMF, rt, 45 min, 96%; (d) 
An appropriate N,N-dimethylbenzamide, POCl3, 1,4-dioxane, mw, 100 °C, 3–5 h, 63% (6), 
75% (7), 39% (27), 43% (28); (e) NaOH, H2O, MeOH, THF, rt, 0.5–28 h, 82% (8), 87% (9), 
34% (14), 6% (19); (f) i) EDC·HCl, HOBt·H2O, DMF, 0 °C, 15 min, rt, 1 h, ii) NH3 (aq), rt, 
2.5–4 h, 87% (10), 35% (25), 85% (30) (g) Benzoyl chloride, AlCl3, DCM, 0 °C, 30 min, rt, 
4–23 h, 87% (11), 73% (31); (h) NIS, DCM, 0 °C, 30 min, rt, 3.5 h, 98%; (i) An appropriate 
phenylboronic acid, Pd(dppf)Cl2, BINAP, Cs2CO3, toluene, mw, 110 °C, 1 h, 84% (18), 88% 
(23); (j) (Chloromethylene)dimethyliminium chloride, DCM, 0 °C, 1 h, 61% (20), 15% (21); 
(k) NIS, DCM, 0 °C, 1.5 h, rt, 19 h, 98%; (l) NaOH, H2O, THF, rt, 2 h, 92% (24), 78% (29); 
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(m) i) LDA, THF, 0 °C, 10 min, rt, 20 min, ii) Methyl chloroformate, –78 °C, 10 min, –78 °C 
→ 0 °C, 45 min, 52%. 
 
Since we did not succeed in adding the second benzoyl group to the five-membered ring of 
6 under the modified Vilsmeier–Haack conditions, we used a Friedel–Crafts acylation instead 
to obtain 11 in 87% yield (Scheme 1). Applying the same Friedel–Crafts conditions for 
compound 7 led to a mixture of 12 and 13 in low yield. These two compounds were not 
separable from each other despite several attempts by flash chromatography.  
Additionally, we noticed that the carboxylic acid 29 is prone to decarboxylation and we failed 
in converting it to the corresponding primary amide. Only the decarboxylated product 30 was 
obtained in 85% yield. 
Compounds 32–39 have been synthesized with another route developed for 1-
acyloxyazulene derivatives, and their synthetic procedures have been described in detail 
previously.[22] 
 
2.3 Binding and Ca2+ elevation. We first screened compounds 6–25 and 27–39 using a 
competition binding assay in Chinese hamster ovary-K1 (CHO) cells heterologously 
expressing high densities of human OX1 and OX2 receptors.[29,30] The binding of each 
compound was measured at a single concentration, 10 µM, in competition with 1 nM [125I]-
orexin-A (see Experimental Section). As a result, twelve compounds (8, 20–22, 30, 32–38) 
showed clear (>30%) and statistically significant inhibition of [125I]-orexin-A binding to either 
or both receptor subtypes (Table 1, Figure 1A). Unexpectedly, six compounds (7, 9, 17, 19, 27, 
and 28) significantly increased the binding of [125I]-orexin-A to the OX1 receptors and to a 
lesser extend to the OX2 receptors (i.e. the % inhibition is negative in Table 1; filled circles in 
Figure 1A). This effect will be discussed in more detail below (see 2.4 Potentiation of orexin-
A binding and Ca2+ response).  
Then, we determined the inhibitory constants for the two most promising compounds using 
a Ca2+ elevation assay (Supporting Information Figure S4). Compound 22 had Ki values of 4.8 
and 3.6 µM and 32 had Ki values 7.6 and 8.6 µM, for the OX1 and OX2 receptors, respectively 
(Table 1). It should be noted that concentrations only up to 10 µM were used for curve-fitting, 
which prevented the responses to reach a plateau. This was due to avoid over-estimations at 
high compound concentrations (due e.g. to aggregation). The reported affinities are thus not 
absolute and therefore should be considered as apparent Ki values. 
 
Table 1. Inhibition of [125I]-orexin-A binding at 10 µM concentration (% inhibition) and Ki 
values of 19, 22 and 32 as determined upon competition with orexin-A in the Ca2+ assay (µM). 
Data are shown as averages of values determined in 3–4 independent experiments in 
quadruplicate. *: P < 0.05. 
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Compound R1 R3 R6 Inhibition of [125I]-orexin-A 
binding (at 10 µM compound 
concentration; %), and Ki (µM; 
shown in parentheses) 
 
    OX1 OX2 
 
22 
 
 
 
40.7 ± 13.0% * 
(4.8 ± 1.8 µM) 
47.2 ± 6.8% * 
(3.6 ± 1.1 µM) 
 
32 
  
 24.5 ± 10.7% * 
(7.6 ± 2.0 µM) 
46.7 ± 10.7% * 
(8.6 ± 2.8 µM) 
 
21 
 
 
 
37.8 ± 6.0% * 44.1 ± 9.5% * 
33 
   
23.0 ± 4.8% * 39.9 ± 7.1% * 
20 
 
 
 
25.0 ± 9.7% * 37.2 ± 11.1% * 
34 
 
  –4.5 ± 2.5% * 36.0 ± 7.6% * 
35 
 
  18.2 ± 2.8% * 35.6 ± 4.1% * 
36 
 
  0.1 ± 12.9% 34.3 ± 9.1% * 
37 
 
  9.8 ± 10.8% 33.2 ± 10.2% * 
8 
 
 
 
11.0 ± 16.5% 32.9 ± 12.0% * 
38 
 
  –2.4 ± 12.5% 32.3 ± 9.2% * 
30 
 
  38.3 ± 0.8% * 31.0 ± 15.6% 
6 
 
 
 
7.2 ± 17.2% 28.9 ± 8.5% * 
14 
  
 
–10.4 ± 6.1% 27.0 ± 12.5% 
A 47:53 
mixture of 
12 and 13 
 
 
 
18.3 ± 8.5% * 26.4 ± 7.8% * 
A 47:53 
mixture of 
15 and 16 
 
 
 
19.9 ± 11.3% * 25.6 ± 8.8% * 
39 
 
  8.0 ± 7.0% 24.3 ± 4.2% * 
   
 
 7 
24 
   
16.2 ± 8.1% * 21.5 ± 10.1% * 
18 
  
 
8.4 ± 12.3% 19.1 ± 9.6% 
10 
 
 
 
13.6 ± 10.5% 18.0 ± 13.9% 
25 
   
6.1 ± 8.5% 16.7 ± 11.8% 
29 
 
 
 
8.6 ± 13.3% 11.2 ± 10.4% 
23 
   
8.5 ± 8.9% 1.8 ± 3.4% 
9 
 
 
 
–81.5 ± 18.6% * 1.0 ± 5.8% 
28 
 
 
 
–30.4 ± 10.6% * 1.0 ± 3.6% 
27 
 
 
 
–37.7 ± 8.1% * –4.3 ± 18.7% 
17 
 
 
 
–34.9 ± 2.1% * –5.4 ± 8.2% 
11 
  
 
–10.6 ± 16.1 % –14.5 ± 12.4 % 
19 
  
 
–24.0 ± 4.8% * 
(7.5 ± 0.9 µM) 
–16.9 ± 16.4% 
(4.9 ± 2.0 µM) 
 
31 
  
 
–21.4 ± 11.9% –20.4 ± 11.2% 
7 
 
 
 
–60.5 ± 19.8% * –47.4 ± 11.4% * 
 
In addition, we screened the compounds 6–25 and 27–39 for the agonist activity in a Ca2+ 
elevation assay at 10 µM concentration (Figure 1B). In the screening, compounds 6, 7 and 27 
caused a Ca2+ elevation of 5–12% of the maximum response (Emax) to orexin-A at both receptor 
subtypes, while the other compounds did not cause notable Ca2+ elevation. Since the observed 
Ca2+ elevation is not necessarily due to orexin receptor agonism, we tested compounds 6, 7 and 
27 also in control CHO-K1 cells (not expressing orexin receptors). In the OX2-expressing cells, 
the responses to 7 and 27 were approximately 5 %-units higher than those in the control cells 
(Figure 1C). We confirmed this observation by assessing the Ca2+ responses to 7 and 27 in the 
presence of an excess of known orexin receptor antagonists, the OX1-selective 41 (SB-334867) 
and OX2-selective 42 (TCS-1102), in OX1- and OX2-expressing cells, respectively (for 
structures of 41 and 42, see Supporting Information Figure S5). The orexin receptor-specific 
responses, i.e. the response above the control cell response and the response suppressed by the 
antagonist, were fully in line (data not shown). Altogether, this suggests compounds 7 and 27 
to act as weak OX2 receptor agonists. The Ca
2+ responses to 7 and 27 at the OX1 receptors and 
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6 at both orexin receptor subtypes were of similar magnitude as those of control cells, and thus 
these responses appeared nonspecific (Figure 1C).  
  
 
Figure 1. A. Inhibition of [125I]-orexin-A binding screened with all of the compounds at 10 µM 
concentration, n=3−4. B. Screening of Ca2+ responses of all compounds at 10 µM concentration 
given as a percentage of Emax of orexin-A, n=2. In A and B, compounds which enhance [
125I]-
orexin-A binding significantly (i.e. give negative inhibition values) are marked as filled circles. 
C. Total Ca2+ responses and specific (orexin receptor-mediated; assessed utilizing control CHO 
cells) Ca2+ responses of the three compounds, which displayed highest Ca2+ response in the 
screening. The responses were normalized to the Emax of orexin-A separately before averaging. 
n=3−4 D. The effects of the compounds at 10 µM concentration on the orexin-A response in 
the Ca2+ elevation assay. E. The effects of three most promising OX1 receptor potentiators on 
the Ca2+ responses elicited by 0.02–0.03 nM orexin-A and 60 nM ATP (corresponding to the 
EC20 of each ligand; see the text for the details). The responses were separately normalized to 
the control orexin-A or ATP response, respectively, for each independent experiment before 
averaging. The significances were calculated for the Ca2+ responses as compared with the 
corresponding control. ns (not significant) P > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001; n = 
3−4.  
 
2.4 Potentiation of orexin-A binding and Ca2+ response. Potentiation of the actions of 
orexin-A is the outcome of several interconnected processes and is difficult to apprehend as a 
whole. Such a potentiation may combine allosteric actions both intra-receptor and through 
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dimers or oligomers, formation of a ternary receptor–orexin-A–potentiator complex, and 
indirect effect through extracellular and intracellular Ca2+ levels or activation of downstream 
signaling machinery.[30–34] 
In particular, orexin-A binding displays self-potentiation (positive cooperativity),[30] and 
we have observed a similar effect with small molecular ligands as well.[9] Here, compounds 
7, 9, 17, 19, 27 and 28 promoted [125I]-orexin-A binding. This effect is characterized by 
concentration-response curves with a bell-shaped initial response, i.e. [125I]-orexin-A binding 
initially increases before being reduced at higher concentrations of unlabeled orexin-A or a 
small molecular competitor. Since we screened the binding at a single concentration (Table 1, 
Figure 1A), there is no indication that, for example, compound 9 (binding assay values –81.5 
± 18.6% on OX1 and 1.0 ± 5.8% on OX2) would potentiate [
125I]-orexin-A binding more 
effectively than 7 (–60.5 ± 19.8% on OX1 and –47.4 ± 11.4% on OX2), because these data 
points can be either from the ascending or the descending part of their concentration-response 
curves. 
Given that the orexin-A peptide occupies a single site at each receptor, the self-potentiation 
of orexin-A binding most likely occurs through receptor dimers or oligomers. An important 
correlate is that if small molecules are able to potentiate orexin-A binding in the same way, 
they also likely bind to the orthosteric binding site. This allows us to reconcile the diverse 
pharmacology observed (antagonists, weak agonists, potentiators) under the parsimonious idea 
that azulene-based compounds all dock to the same binding site. Yet, because the potentiating 
effect of orexin-A binding occurs only at low orexin-A concentrations, i.e. at low receptor 
occupancy, it is not the major factor in the observed potentiation of Ca2+ elevation (described 
below).  
The other factor to consider is calcium, both extracellular and intracellular. Binding of the 
orexin-A peptide requires extracellular Ca2+, as suggested by the decrease of [125I]-orexin-A 
binding when extracellular Ca2+ levels are reduced.[30] Whether increasing the intracellular 
Ca2+ levels would potentiate orexin-A binding has, however, not been studied previously. Here, 
compounds 7 and 27 caused an intracellular Ca2+ elevation at both OX1- and OX2-expressing 
cells, which could play a role in the potentiation of [125I]-orexin-A binding if Ca2+ efflux would 
occur (Table 1; Figure 1A–B). However, agonism does not offer any explanation in the case of 
compounds 9, 17, 19, and 28 that do not elevate cytosolic Ca2+. Another possible mechanism 
of the potentiation of the actions of orexin-A by intracellular Ca2+ is the activation of the 
downstream molecular machinery.[30–34]  
We decided to study further the compounds, which potentiated orexin-A binding. Thus, we 
assessed the Ca2+ responses of the compounds 7, 9, 17, 19, 27 and 28 in a presence of 0.02–
0.03 nM orexin-A; the orexin-A concentration was separately adjusted in each bath of the cells 
to approximately correspond the EC20 of the orexin-A. We expanded the pool of tested 
compounds to 6, 8, 11, 14, 29 and 31 that potentiated the binding of orexin-A to OX1 receptors 
on some of the individual experiments (data not shown). Because changes in the intracellular 
Ca2+ levels might potentiate the response to orexin-A, we used controls that mimicked the 
effect of the compounds on the intracellular Ca2+. For compounds 8, 9, 11, 14, 17, 19, 28, 29 
and 31, which did not trigger Ca2+ elevation, we used 10 nM ATP as a control; this ATP 
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concentration does not cause a detectable Ca2+ elevation by itself. For 6, 7 and 27, we used 30 
nM ATP as a control, since this concentration of ATP elevates the intracellular Ca2+ levels to 
the same magnitude as the Ca2+ responses to these compounds.  
As a result, with the exception of 19, all tested compounds potentiated the Ca2+ response to 
orexin-A by at least 1.4-fold on OX1 receptors at 10 µM concentration (Figure 1D, Supporting 
Information Figure S6). Interestingly, the potentiation effect was specific to the OX1 receptors, 
except for compound 28 that showed a weak potentiation at the OX2 receptors too (Figure 1D). 
The potentiating effects of compounds 8, 9, 11, 14, 17, 28, 29 and 31 were significantly higher 
than that of the control (10 nM ATP; Figure 1D). The potentiation of the Ca2+ response to 
orexin-A induced by compounds 6, 7 and 27, instead, was not significantly different from that 
of 30 nM ATP (Supporting Information Figure S6). This might indicate that the compound-
mediated increase of the intracellular Ca2+ levels potentiated the orexin-A response, not these 
compounds per se. It may also be that the Ca2+ elevation triggered by these compounds makes 
the detection of potentiation effects too challenging. Altogether, out of the four compounds 
that promoted [125I]-orexin-A binding at the concentration tested, three (9, 17 and 28 but not 
19) were found to be able to significantly promote orexin-A mediated Ca2+ elevation. 
Furthermore, all five additional compounds tested (8, 11, 14, 29 and 31) potentiated the Ca2+ 
response to orexin-A. Thus, it is possible that also other potentiators of orexin-A response may 
be found among the azulene derivatives presented in this study.  
At that stage, the most promising compounds 11, 17 and 28 induced an approximately two-
fold increase in the Ca2+ response to orexin-A at 10 µM concentration. We verified the 
concentration-dependency of their action by testing also their potentiation effects at 1 µM and 
5 µM concentrations. Limitations in water solubility of these compounds prevented us to study 
higher concentrations. As Figure 1E illustrates, all these compounds potentiated the effect of 
orexin-A in a concentration-dependent manner. Compound 28 was the best one, increasing the 
orexin-A response 1.4-fold at 5 µM and 2.0-fold at 10 µM concentrations. The observed 
potentiation by compound 28 is of similar magnitude to previously reported orexin receptor 
potentiators.[13] However, Lee et al. utilized a cAMP assay, and it is difficult to compare it to 
our results based on Ca2+ elevation.  
Finally, we tested the effects of compounds 6, 7, 8, 9, 11, 14, 17, 19, 27, 28, 29 and 31 on 
the actions of ATP in OX1 receptor-expressing cells. ATP causes a Ca
2+ signal read-out similar 
to orexin-A, but not via the orexin receptors. None of the tested compounds affected the 
response to ATP in an assay set-up identical to the one used with orexin-A (Figure 1E; for all 
tested compounds, see Supporting Information Figure S7). Together with the absence of 
potentiation at the OX2, this provides a strong evidence for a mechanism of the Ca
2+ response 
potentiation to be mediated through OX1 receptors.  
Unlike the other compounds increasing the [125I]-orexin-A binding at 10 µM concentration, 
compound 19 neither acted as a weak orexin receptor activator nor a potentiator of orexin-A-
mediated Ca2+ elevation (Figure 1D). We conducted further investigations with this compound 
and determined Ki values of 7.5 µM and 4.9 µM for OX1 and OX2 receptors, respectively (Table 
1; Supporting Information Figure S4).  
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The set of azulene compounds is congeneric, which makes it possible to draw preliminary 
inferences of their structure-activity relationships (SARs). For potentiation, ester in the 6-
position of azulene is preferred over the corresponding carboxyl group (e.g. compounds 11 vs. 
14, and 28 vs. 29); in contrast, for binding there is a slight preference for carboxyl group over 
the corresponding ester (e.g. compounds 20 vs. 21, and 23 vs. 24). It can be that the carboxyl 
group in the 6-position increases binding of the compounds to the orthosteric orexin-A binding 
site, or that the ester derivatives potentiate the [125I]-orexin-A binding, which masks the 
competition between the compound and [125I]-orexin-A. In the latter case, it is possible that the 
compounds with the ester in the 6-position actually bind better to OX1 receptors than the 
binding data suggest. Either way, these results offer an interesting starting point for further 
compound development.  
A consideration in this study is that we cannot critically assess the usefulness of the virtual 
screen. The final hit rate is high – higher that in our previously study [35] —which by itself 
suggests a positive influence. Nonetheless, we neither can claim for certainty that the binding 
site would be common among the presented azulenes, nor that it would be orthosteric. We are 
currently setting up assays to get an experimental answer to these questions, yet it is beyond 
the scope of this manuscript. Since the virtual screen was targeted at the orthosteric site, it 
leaves open whether we are right for the right reasons, which is a prevalent question in virtual 
screens. Consequently, we have avoided presenting a speculative retrospective analysis of the 
binding modes that would divert this manuscript from its main message. Secondly, we lack 
true benchmarks to assess the performance of the screen, since we do not know what would 
have happened without a computational selection. The compounds are congeneric, and as such 
expected to share some similarities in their activities, and this makes it difficult to reasonably 
set a “random” rate for screening. Nonetheless, this does not diminish the value of the 
computational selection. 
 
3 CONCLUSIONS 
Twelve novel azulene-based compounds out of 33 (four of them tested as mixtures), 
prioritized through a virtual screening protocol, showed noticeable binding to the orexin 
receptors. The two most promising binders, 22 and 32, were orthogonally tested in a functional 
assay and found to have Ki values in the low micromolar range. Additionally, compounds 7 
and 27 acted as weak orexin receptor agonists, inducing orexin receptor-mediated Ca2+ 
responses of 5% of the maximal response to orexin-A. This high hit rate supports the use of the 
prospective virtual screen, even if the protocol does not enable a fair comparison with a random 
selection. 
A set of six compounds enhanced [125I]-orexin-A binding. Upon examination of  a larger 
compound subset, six out of twelve compounds tested showed significant potentiation of the 
response at sub-EC50 concentrations of orexin-A; three of them, 11, 17 and 28, increased the 
orexin-A-mediated Ca2+ response in concentration-dependent manner, with two-fold 
potentiation at 10 µM. Previously, only one series of compounds have been reported to 
potentiate the actions of orexin-A.  
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In this study, we have presented a body of evidence that indicates a direct mechanism of 
action through orexin receptors: (1) weak agonism that can be suppressed by specific 
antagonists and evidenced in the control cells not expressing orexin receptors, (2) competition 
binding with [125I]-orexin-A as well as potentiation that is possibly mediated through receptor 
dimers, (3) potentiation of orexin-A response in OX1 but not OX2-expressing cells, which was 
significantly better than ATP controls, and (4) absence of colloidal aggregation for compounds 
19, 22 and 32 at the used concentration range. We believe that such a concordant picture point 
to a specific direct interaction between azulene-based compounds and orexin receptors. 
How these findings translate into one or several interaction sites remains highly speculative 
and is beyond the scope of this manuscript. Indeed, while this study includes a significant 
characterization of the most intriguing compounds, the pharmacological work will extend 
beyond it; further studies to understand e.g. the potentiation effect and receptor dimerization 
need to be conducted. Furthermore, we plan to explore further the landscape of azulene 
derivatives to analyze their SARs. Finally, future efforts will be directed to the identification 
of more potent compounds. 
 
4 EXPERIMENTAL SECTION 
4.1 Computational studies. Building the azulene-based virtual library. An azulene scaffold 
was attached with three sets of manually designed R-groups (positions 1, 3 and 6; see Table 1) 
by combinatorial database building tool of Schrödinger Maestro 2015v1,[36] producing a 
database of 168084 compounds (after removing the duplicates due to the scaffold symmetry). 
We filtered out compounds with molecular weight over 500 g/mol, resulting in a final library 
of 70038 compounds. Subsequently, a set of starting points (main species predicted at pH 7 ± 
2) of each compound were built by Schrödinger’s LigPrep tool utilizing Epik for generating 
protonation states. Taking into account the possible protonation states, the library included 
144000 starting points for virtual screening. 
Virtual screening. To screen the virtual library we utilized Glide of Schrödinger Maestro 
2015v3[23] with SP parameters. Screening was conducted on the crystal structure of OX2 
receptor[24] in the absence of the binding site waters (for more information about selecting the 
screening protocol see Supporting Information page S8). To monitor the performance of the 
docking, the virtual library was seeded with 117 dual or OX2R selective orexin receptor 
antagonists. The docking protocol was able to retrieve 25% of these known actives in the top 
10% of the database, with area under the accumulation curve (ROC) being 0.75. Furthermore, 
40 (suvorexant), an orexin receptor antagonist present in the crystal structure, was docked 
among these active compounds, and the docked conformation compared to the one co-
crystallized with OX2R. Compound 40 scored to top 1.6% of the library and its conformation 
was highly similar to the binding conformation of 40 in the crystal structure (pairwise heavy 
atom RMSD 0.54 Å). Glide’s “docking score”[23] was used for all ranking. 
R-group analysis and compound selection. The 5% top-scoring poses (i.e. 7200 poses) were 
analyzed using the R-group analysis tool of Schrödinger Canvas.[23] The gained understanding 
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of the most favorable R-groups supported the visual examination of the 200 top-scoring 
docking poses. 
 
4.2 Chemistry. All compounds were characterized by 1H and 13C NMR spectroscopy using 
a Bruker Avance III 400 MHz spectrometer. Chemical shifts are reported in parts per million 
(ppm) relative to the residual solvent signals: CDCl3 7.26 and 77.17 ppm, DMSO-d6 2.50 and 
39.52 ppm, acetone-d6 2.05 and 29.84 ppm for 
1H and 13C NMR, respectively. The progress of 
the reactions was monitored by thin-layer chromatography on silica gel 60-F254 plates. Silica 
gel (SiO2) 60 (230−400 mesh) was used in flash chromatography purifications. Microwave 
reactions were conducted in sealed reaction vessels using a Biotage Initiator+ instrument 
equipped with an external IR sensor to detect the reaction temperature. Mass spectrometric 
analysis were performed with a Waters Synapt G2 HDMS mass spectrometer using 
electrospray ionization (ESI). The purity was determined by UPLC-MS with diode-array 
detector. The purity of the all biologically tested compounds was 95% or higher, except for 27 
with 94% purity. 1H NMR of 27 shows only hardly visible impurities. 
6-Carboxyazulene (3). Oxone (1.23 g, 4.00 mmol) was added to a solution of 6-
formylazulene (0.625 g, 4.00 mmol) in DMF (20 mL). The blue reaction mixture was stirred 
at room temperature for 3 h. The reaction mixture was quenched by a 1 M aqueous solution of 
HCl (20 mL) on ice bath and EtOAc (80 mL) was added. The organic phase was washed with 
a 1 M aqueous solution of HCl (3 × 60 mL) and brine (60 mL), dried over anhydrous Na2SO4, 
filtered and evaporated to provide dark green solid. The crude product was purified by flash 
chromatography (n-heptane/EtOAc/AcOH 75:24:1) to give 3 as a green, amorphous solid 
(0.332 g, 48%). 1H NMR (400 MHz, acetone-d6) δ 8.55 (d, J = 10.4 Hz, 2H), 8.11 (d, J = 10.8 
Hz, 2H), 8.06 (t, J = 3.8 Hz, 1H), 7.51 (d, J = 3.6 Hz, 2H). 13C NMR (101 MHz, acetone-d6) δ 
169.4, 142.3, 140.9, 137.4, 135.8, 123.9, 119.8. HRMS (ESI-QTOF) m/z: [M - H]- Calcd for 
C11H7O2 171.0446; Found 171.0444. 
Methyl azulene-6-carboxylate (4). K2CO3 (0.66 g, 4.8 mmol) and iodomethane (0.24 mL, 
3.8 mmol) were added to the blue solution of 3 (0.33 g, 1.9 mmol) in DMF (10 mL). The 
reaction mixture was stirred at room temperature for 45 min. Et2O (60 mL) and a 1 M aqueous 
solution of HCl (30 mL) were added to the reaction mixture on ice bath. Et2O phase was washed 
with a 1 M aqueous solution of HCl (30 mL), a saturated solution of NaHCO3 (30 mL) and 
brine (30 mL), dried over anhydrous Na2SO4, filtered and evaporated to provide green-blue 
solid. The crude product was purified by flash chromatography (n-heptane/EtOAc 85:15) to 
give 4 as a green-blue, amorphous solid (0.34 g, 96%). 1H NMR (400 MHz, CDCl3) δ 8.42 (d, 
J = 10.8 Hz, 2H), 8.07–8.04 (m, 3H), 7.47 (d, J = 3.6 Hz, 2H), 4.00 (s, 3H). 13C NMR (101 
MHz, CDCl3) δ 168.9, 141.5, 140.4, 136.1, 134.9, 123.2, 119.0, 53.2. HRMS (ESI-QTOF) m/z: 
[M + H]+ Calcd for C12H11O2 187.0759; Found 187.0758. 
N,N-Dimethyl-4-(trifluoromethyl)benzamide (5). A 2 M solution of Me2NH in THF (12.5 
mL, 25.0 mmol) was added dropwise to a solution of 4-(trifluoromethyl)benzoyl chloride (1.49 
mL, 10.0 mmol) in anhydrous DCM (10 mL) on ice bath under argon. The resulting mixture 
was stirred at 0 °C for 45 min. The reaction mixture was quenched with a 1 M aqueous solution 
of HCl (20 mL) on ice bath and DCM (50 mL) was added. The organic phase was washed with 
   
 
 14 
a 1 M aqueous solution of HCl (2 × 30 mL), a saturated aqueous solution of NaHCO3 (30 mL) 
and brine (30 mL), dried over anhydrous Na2SO4, filtered and evaporated to give 5 as a white, 
amorphous solid (2.17 g, quant.). 1H NMR (400 MHz, CDCl3) δ 7.67 (d, J = 8.0 Hz, 2H), 7.52 
(d, J = 7.6 Hz, 2H), 3.12 (s, 3H), 2.96 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 170.3, 140.0, 
131.6 (q, 2JC,F = 32.8 Hz), 127.5, 125.6 (q, 
3JC,F = 3.8 Hz), 123.9 (q, 
1JC,F = 273.4 Hz), 39.5, 
35.5. 
General procedure for the synthesis of compounds 6, 7, 27, 28. POCl3 (4 equiv) was added 
to a solution of the appropriate azulene derivative and N,N-dimethylbenzamide derivative (4.3 
equiv) in anhydrous 1,4-dioxane (4 mL) under argon. The resulting solution was heated under 
microwave irradiation at 100 °C for 2–5 h. The reaction mixture was poured into a 1 M aqueous 
solution of NaOH (80–100 mL) and extracted with DCM (60 + 30 mL). The organic phases 
were combined and washed with water (50 mL), dried over anhydrous Na2SO4, filtered and 
evaporated to provide a crude product, which was purified by flash chromatography.  
Methyl 1-benzoylazulene-6-carboxylate (6). Compound 4 (0.317 g, 1.70 mmol) and N,N-
dimethylbenzamide (1.09 g, 7.30 mmol) with a 3-h reaction time gave a green-blue oil, which 
after flash chromatography (n-heptane/EtOAc 85:15) yielded 6 as a green, amorphous solid 
(0.309 g, 63%). 1H NMR (400 MHz, CDCl3) δ 9.73 (d, J = 10.4 Hz, 1H), 8.57 (d, J = 10.4 Hz, 
1H), 8.46 (dd, J = 10.4, 1.6 Hz, 1H), 8.32 (dd, J = 10.4, 1.6 Hz, 1H), 8.22 (d, J = 4.4 Hz, 1H), 
7.87–7.84 (m, 2H), 7.60–7.56 (m, 1H), 7.53–7.49 (m, 2H), 7.37 (d, J = 4.4 Hz, 1H), 4.04 (s, 
3H). 13C NMR (101 MHz, CDCl3) δ 192.9, 168.0, 146.0, 145.2, 142.8, 141.0, 138.2, 137.6, 
137.1, 131.6, 129.7, 129.2, 128.4, 127.4, 125.9, 118.6, 53.5. HRMS (ESI-QTOF) m/z: [M + 
H]+ Calcd for C19H15O3 291.1021; Found 291.1025. 
Methyl 1-[4-(trifluoromethyl)benzoyl]azulene-6-carboxylate (7). Compound 4 (0.372 g, 
2.00 mmol) and 5 (1.09 g, 7.30 mmol) with a 5-h reaction time gave a green solid, which after 
flash chromatography (n-heptane/EtOAc 85:15) yielded 7 as a green, amorphous solid (0.540 
g, 75%). 1H NMR (400 MHz, CDCl3) δ 9.80 (d, J = 10.4 Hz, 1H), 8.60 (d, J = 10.4 Hz, 1H), 
8.51 (dd, J = 10.4, 1.6 Hz, 1H), 8.37 (dd, J = 10.4, 1.6 Hz, 1H), 8.14 (d, J = 4.4 Hz, 1H), 7.93 
(d, J = 8.0 Hz, 2H), 7.78 (d, J = 8.0 Hz, 2H), 7.37 (d, J = 4.4 Hz, 1H), 4.05 (s, 3H). 13C NMR 
(101 MHz, CDCl3) δ 191.5, 167.8, 146.5, 145.1, 144.2, 143.1, 138.6, 137.9, 137.4, 133.0 (q, 
2JC,F = 32.7 Hz), 129.8, 129.7, 128.0, 125.4 (q, 
3JC,F = 3.8 Hz), 125.1, 122.6, 118.9, 53.6. HRMS 
(ESI-QTOF) m/z: [M + H]+ Calcd for C20H14O3F3 359.0895; Found 359.0897. 
Methyl 2-(1-benzoylazulen-6-yl)acetate (27). Compound 26 (0.521 g, 2.60 mmol) and N,N-
dimethylbenzamide (1.68 g, 11.2 mmol) with a 2-h reaction time gave a brown oil, which after 
flash chromatography (n-heptane/EtOAc 3:1) yielded 27 as a purple, amorphous solid (0.310 
g, 39%). 1H NMR (400 MHz, CDCl3) δ 9.63 (d, J = 10.0 Hz, 1H), 8.44 (d, J = 10.0 Hz, 1H), 
8.05 (d, J = 4.0 Hz, 1H), 7.85–7.83 (m, 2H), 7.59–7.54 (m, 2H), 7.52–7.46 (m, 3H), 7.28 (d, J 
= 4.4 Hz, 1H), 3.91 (s, 2H), 3.73 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 193.0, 171.1, 146.4, 
144.4, 142.5, 141.4, 140.8, 138.5, 137.8, 131.3, 130.7, 129.7, 129.2, 128.2, 125.6, 118.2, 52.6, 
46.8. HRMS (ESI-QTOF) m/z: [M + H]+ Calcd for C20H17O3 305.1178; Found 305.1176. 
Methyl 2-[1-[4-(trifluoromethyl)benzoyl]azulen-6-yl]acetate (28). Compound 26 (0.400 
g, 2.00 mmol) and 5 (1.87 g, 8.60 mmol) with a 2-h reaction time gave a brown solid, which 
after flash chromatography (manual gradient of n-heptane/EtOAc 3:1 → 2:1) yielded 28 as a 
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purple, amorphous solid (0.322 g, 43%). 1H NMR (400 MHz, CDCl3) δ 9.69 (d, J = 10.0 Hz, 
1H), 8.46 (d, J 10.0 Hz, 1H), 7.97 (d, J = 4.0 Hz, 1H), 7.92 (d, J = 8.0 Hz, 2H), 7.76 (d, J = 8.0 
Hz, 2H), 7.63 (dd, J = 10.2, 1.8 Hz, 1H), 7.52 (dd, J = 10.4, 1.6 Hz, 1H), 7.28 (d, J = 4.4 Hz, 
1H), 3.93 (s, 2H), 3.73 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 191.5, 171.0, 146.9, 144.8, 
144.6, 142.4, 141.0, 138.7, 138.1, 132.7 (q, 2JC,F = 32.6 Hz), 131.4, 129.9, 129.7, 125.3 (q, 
3JC,F 
= 3.8 Hz), 124.7, 124.0 (q, 1JC,F = 273.5 Hz), 118.5, 52.6, 46.8. HRMS (ESI-QTOF) m/z: [M 
+ H]+ Calcd for C21H16O3F3 373.1052; Found 373.1052. 
General procedure for the synthesis of compounds 8, 9, 14, 19. The appropriate ester 
derivative was dissolved in THF (2–13 mL) and MeOH (0.2–0.65 mL). A 2 M aqueous solution 
of NaOH (0.2–2.2 mL) was added to the blue solution and the resulting mixture was stirred at 
room temperature for 1–28 h. A 1 M aqueous solution of HCl (5 mL) was added to the reaction 
mixture on ice bath and then the mixture was extracted with EtOAc (40–50 mL). The organic 
phase was washed with a 1 M aqueous solution of HCl (2 × 20–25 mL) and brine (20–25 mL), 
dried over anhydrous Na2SO4, filtered and evaporated to provide a crude product, which was 
purified by flash chromatography. 
1-Benzoylazulene-6-carboxylic acid (8). Compound 6 (0.099 g, 0.34 mmol) with a 1.5-h 
reaction time gave a green solid, which after flash chromatography (EtOAc/AcOH 99:1) 
yielded 8 as a green, amorphous solid (0.077 g, 82%). 1H NMR (400 MHz, DMSO-d6) δ 9.62 
(d, J = 10.4 Hz, 1H), 8.81 (d, J = 10.4 Hz, 1H), 8.44 (dd, J = 10.4, 1.6 Hz, 1H), 8.33 (dd, J = 
10.0, 1.6 Hz, 1H), 8.18 (d, J = 4.4 Hz, 1H), 7.80–7.77 (m, 2H), 7.67–7.62 (m, 1H), 7.59–7.54 
(m, 2H), 7.51 (d, J = 4.4 Hz, 1H). 13C NMR (101 MHz, DMSO-d6) δ 191.5, 168.3, 145.3, 
144.3, 141.7, 140.4, 139.6, 137.9, 137.0, 131.6, 129.1, 128.8, 128.4, 127.6, 124.7, 118.8. 
HRMS (ESI-QTOF) m/z: [M + H]+ Calcd for C18H13O3 277.0865; Found 277.0866 
1-[4-(Trifluoromethyl)benzoyl]azulene-6-carboxylic acid (9). Compound 7 (0.047 g, 0.13 
mmol) with a 1.5-h reaction time gave a green-blue solid, which after flash chromatography 
(EtOAc/AcOH 99:1) yielded 9 as a dark green, amorphous solid (0.039 g, 87%). 1H NMR (400 
MHz, DMSO-d6) δ 9.70 (d, J = 10.4 Hz, 1H), 8.85 (d, J = 10.4 Hz, 1H), 8.50 (dd, J = 10.4, 1.6 
Hz, 1H), 8.38 (dd, J = 10.2, 1.4 Hz, 1H), 8.17 (d, J = 4.4 Hz, 1H), 7.98–7.92 (m, 4H), 7.52 (d, 
J = 4.0 Hz, 1H). 13C NMR (101 MHz, DMSO-d6) δ 190.3, 168.2, 145.8, 144.6, 144.1, 142.0, 
140.2, 138.2, 137.3, 131.0 (q, 2JC,F = 31.9 Hz), 129.7, 129.6, 128.2, 125.4 (q, 
3JC,F = 3.8 Hz), 
124.0 (q, 1JC,F = 273.5 Hz), 123.9, 119.1. HRMS (ESI-QTOF) m/z: [M + H]
+ Calcd for 
C19H12O3F3 345.0739; Found 345.0741. 
1,3-Dibenzoylazulene-6-carboxylic acid (14). Compound 11 (0.12 g, 0.30 mmol) with a 1-
h reaction time gave a brown solid, which after flash chromatography (manual gradient of 
THF/AcOH/MeOH 99:1:1 → 96:2:2) yielded 14 as a green, amorphous solid (0.039 g, 34%). 
1H NMR (400 MHz, DMSO-d6) δ 9.83 (d, J = 11.2 Hz, 2H), 8.75 (d, J = 11.2 Hz, 2H), 8.17 (s, 
1H), 7.85–7.82 (m, 4H), 7.65–7.61 (m, 2H), 7.57–7.53 (m, 4H). 13C NMR (101 MHz, DMSO-
d6) δ 191.6, 167.9, 147.9, 144.8, 143.6, 139.8, 139.1, 132.6, 132.0, 129.3, 128.5, 123.4. HRMS 
(ESI-QTOF) m/z: [M + H]+ Calcd for C25H17O4 381.1127; Found 381.1128 
1-Benzoyl-3-(4-ethoxyphenyl)azulene-6-carboxylic acid (19). Compound 18 (0.17 g, 0.42 
mmol) with a 28-h reaction time gave a brown solid, which after flash chromatography 
(EtOAc/AcOH 99:1) yielded a brownish green solid. The solid was washed an equimixture of 
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DCM and EtOAc to give 19 as a brownish green, amorphous solid (0.010 g, 6%). 1H NMR 
(400 MHz, DMSO-d6) δ 9.59 (d, J = 10.4 Hz, 1H), 8.78 (d, J = 10.4 Hz, 1H), 8.38 (d, J = 10.4 
Hz, 1H), 8.28 (d, J = 10.4 Hz, 1H), 8.19 (s, 1H), 7.85–7.83 (m, 2H), 7.66–7.63 (m, 1H), 7.58–
7.55 (m, 4H), 7.08–7.06 (m, 2H), 4.09 (q, J = 7.0 Hz, 2H), 1.36 (t, J = 7.0 Hz, 3H). 13C NMR 
(101 MHz, DMSO-d6) δ 191.4, 168.2, 157.9, 143.5, 142.5, 140.5, 140.3, 139.7, 137.3, 136.3, 
131.7, 130.7, 130.5, 129.3, 128.8, 128.5, 127.7, 127.3, 123.6, 114.9, 63.2, 14.7. HRMS (ESI-
QTOF) m/z: [M + H]+ Calcd for C26H21O4 397.1440; Found 397.1440. 
1-Benzoylazulene-6-carboxamide (10). Compound 8 (0.069 g, 0.25 mmol) was dissolved 
in DMF (1 mL). The blue solution was cooled to 0 °C and EDC·HCl (0.053 g, 0.28 mmol) and 
HOBt·H2O (0.043 g, 0.28 mmol) were added. The reaction mixture was stirred at 0 °C for 15 
min and at room temperature for 1 h. Aqueous NH3 (25%, 0.048 mL, 0.63 mmol) was added 
and the stirring was continued at room temperature for 2.5 h. H2O (15 mL) was added to the 
reaction mixture and it was extracted with EtOAc (30 mL). The organic phase was washed 
with a 1 M aqueous solution of HCl (15 mL) and a saturated aqueous solution of NaHCO3 (15 
mL), dried over anhydrous Na2SO4, filtered and evaporated to provide a green solid. The crude 
product was purified by flash chromatography (EtOAc/MeOH/Et3N 93:5:2) to give 10 as a 
green, amorphous solid (0.060 g, 87%). 1H NMR (400 MHz, DMSO-d6) δ 9.59 (d, J = 10.4 
Hz, 1H), 8.79 (d, J = 10.4 Hz, 1H), 8.35 (s, 1H), 8.13–8.10 (m, 2H), 8.03 (dd, J = 10.2, 1.4 Hz, 
1H), 7.81 (s, 1H), 7.79–7.77 (m, 2H), 7.66–7.62 (m, 1H), 7.59–7.55 (m, 2H), 7.49 (d, J = 4.0 
Hz, 1H). 13C NMR (101 MHz, DMSO- d6) δ 191.5, 170.1, 145.1, 144.8, 143.4, 141.0, 140.5, 
138.4, 137.4, 131.5, 129.1, 128.4, 127.5, 126.6, 124.5, 118.5. HRMS (ESI-QTOF) m/z: [M + 
H]+ Calcd for C18H14NO2 276.1024; Found 276.1026. 
Methyl 1,3-dibenzoylazulene-6-carboxylate (11). Compound 6 (0.15 g, 0.50 mmol) and 
benzoyl chloride (0.087 mL, 0.75 mmol) were dissolved in anhydrous DCM (3 mL) under 
argon. The reaction mixture was cooled to 0 °C and AlCl3 (0.13 g, 1.0 mmol) was added. The 
brownish red solution was stirred at 0 °C for 30 min and at room temperature for 4 h. An 
additional 1 equiv of AlCl3 (0.067 g, 0.50 mmol) and 1.5 equiv of benzoyl chloride (0.087 mL, 
0.75 mmol) were added, and stirring was continued at room temperature for 20 h. The reaction 
mixture was quenched by a 1 M aqueous solution of HCl (5 mL) on ice bath and DCM (50 
mL) was added. Phases were separated and the organic phase was washed with a 1 M aqueous 
solution of HCl (2 × 25 mL), a saturated solution of NaHCO3 (25 mL) and water (25 mL), dried 
over anhydrous Na2SO4, filtered and evaporated to provide greenish brown solid. The crude 
product was purified by flash chromatography (n-heptane/DCM 1:3 + n-heptane/DCM/EtOAc 
25:70:5) to give 11 as a dark gray, amorphous solid (0.17 g, 87%). 1H NMR (400 MHz, CDCl3) 
δ 9.85 (d, J = 10.8 Hz, 2H), 8.67 (d, J = 11.2 Hz, 2H), 8.36 (s, 1H), 7.86–7.83 (m, 4H), 7.59–
7.55 (m, 2H), 7.51–7.47 (m, 4H), 4.08 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 192.8, 167.3, 
148.6, 145.9, 140.3, 140.2, 139.3, 132.2, 132.0, 129.8, 128.5, 124.9, 53.8. HRMS (ESI-QTOF) 
m/z: [M + H]+ Calcd for C26H19O4 395.1283; Found 395.1288. 
Methyl 1-benzoyl-3-iodoazulene-6-carboxylate (17). Compound 6 (0.058 g, 0.20 mmol) 
was dissolved in anhydrous DCM (1 mL) under argon. The blue solution was cooled to 0 °C 
and NIS (0.11 g, 0.50 mmol) was added. The mixture was stirred at 0 °C for 1 h and then at 
room temperature for 3.5 h. The reaction mixture was eluted through a pad of neutral alumina 
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with DCM (10 mL) and concentrated in vacuo to give 17 as a green, amorphous solid (0.081 
g, 98%). 1H NMR (400 MHz, acetone-d6) δ 9.63 (d, J = 10.4 Hz, 1H), 8.63 (d, J = 10.8 Hz, 
1H), 8.53–8.48 (m, 2H), 8.33 (s, 1H), 7.87–7.85 (m, 2H), 7.69–7.64 (m, 1H), 7.61–7.57 (m, 
2H), 4.04 (s, 3H). 13C NMR (101 MHz, acetone-d6) δ 191.6, 167.9, 151.6, 145.3, 143.1, 141.3, 
140.3, 137.9, 132.6, 130.4, 130.2, 129.3, 128.7, 127.9, 77.0, 53.9. HRMS (ESI-QTOF) m/z: [M 
+ H]+ Calcd for C19H14O3I 416.9987; Found 416.9988. 
Methyl 1-benzoyl-3-(4-ethoxyphenyl)azulene-6-carboxylate (18). A mixture of 
compound 17 (0.071 g, 0.17 mmol), 4-ethoxyphenylboronic acid (0.056 g, 0.34 mmol), 
Pd(dppf)Cl2 (0.0062 g, 0.0085 mmol), BINAP (0.0053 g, 0.0085 mmol) and Cs2CO3 (0.22 g, 
0.68 mmol) in anhydrous toluene (2.5 mL) was heated under microwave irradiation 110 °C for 
1 h under argon. The resulting green mixture was filtered through a small pad of Celite with 
DCM (5 mL) and diluted with DCM (20 mL). The organic phase was washed with water (15 
mL), a saturated aqueous solution of NaHCO3 (15 mL) and brine (15 mL), dried over 
anhydrous Na2SO4, filtered and evaporated to provide a dark green oil. The crude product was 
purified by flash chromatography (manual gradient of n-heptane/DCM/EtOAc 1:1:0 → 
47.5:47.5:5) to give 18 as a green, amorphous solid (0.059, 84%). 1H NMR (400 MHz, CDCl3) 
δ 9.70 (d, J = 10.0 Hz, 1H), 8.70 (d, J = 10.4 Hz, 1H), 8.39 (dd, J = 10.4, 1.6 Hz, 1H), 8.25 (s, 
1H), 8.23 (dd, J = 10.4, 1.6 Hz, 1H), 7.89–7.87 (m, 2H), 7.60–7.56 (m, 1H), 7.53–7.46 (m, 
4H), 7.06–7.02 (m, 2H), 4.12 (q, J = 7.0 Hz, 2H), 4.03 (s, 3H), 1.47 (t, J = 7.0 Hz, 3H). 13C 
NMR (101 MHz, CDCl3) δ 192.8, 168.0, 158.6, 144.8, 143.6, 141.0, 138.7, 137.8, 135.9, 131.7, 
131.7, 130.9, 129.8, 129.0, 128.4, 128.0, 127.2, 124.7, 115.1, 63.8, 53.5, 15.0. HRMS (ESI-
QTOF) m/z: [M + H]+ Calcd for C27H23O4 411.1596; Found 411.1596. 
Methyl 1-formylazulene-6-carboxylate (20). Compound 4 (0.384 g, 2.06 mmol) was 
dissolved in anhydrous DCM (10 mL) under argon. (Chloromethylene)dimethyliminium 
chloride (0.291 g, 2.27 mmol) in anhydrous DCM (15 mL) was added to the blue solution at 0 
°C. The resulting mixture was stirred at 0 °C for 60 min. A 1 M aqueous solution of NaOH (80 
mL) and DCM (25 mL) were added to the reaction mixture on ice bath. Phases were separated 
and aqueous phase was extracted with DCM (30 mL). DCM phases were combined and washed 
with water (50 mL), dried over anhydrous Na2SO4, filtered and evaporated to provide a dark 
green solid. The crude product was purified by flash chromatography (n-heptane/EtOAc 2:1) 
to give 20 as a green, amorphous solid (0.271 g, 61%). 1H NMR (400 MHz, acetone-d6) δ 10.44 
(s, 1H), 9.61 (d, J = 10.4 Hz, 1H), 8.77 (d, J = 10.4 Hz, 1H), 8.49 (d, J = 4.0 Hz, 1H), 8.44 (dd, 
J = 10.2, 1.4 Hz, 1H), 8.34 (dd, J = 10.4, 1.6 Hz, 1H), 7.54 (d, J = 4.0 Hz, 1H), 4.02 (s, 3H). 
13C NMR (101 MHz, acetone-d6) δ 186.8, 168.1, 147.4, 144.9, 141.8, 139.5, 138.8, 136.3, 
129.7, 128.6, 127.8, 120.9, 53.7. HRMS (ESI-QTOF) m/z: [M + H]+ Calcd for 
C13H11O3 215.0708; Found 215.0708. 
1-Formylazulene-6-carboxylic acid (21). The purple NaOH phase from the reaction of 20 
was acidified with a 37% solution of HCl in H2O, and it was extracted with EtOAc (80 mL). 
The organic phase was washed with brine (40 mL), dried over anhydrous Na2SO4, filtered and 
evaporated to give 21 as a brownish green, amorphous solid (0.061 g, 15%). 1H NMR (400 
MHz, DMSO-d6) δ 10.40 (s, 1H), 9.56 (d, J = 10.4 Hz, 1H), 8.82 (d, J = 10.0 Hz, 1H), 8.50 (d, 
J = 4.0 Hz, 1H), 8.44 (dd, J = 10.4, 1.6 Hz, 1H), 8.35 (dd, J = 10.2, 1.4 Hz, 1H), 7.57 (d, J = 
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4.4 Hz, 1H). 13C NMR (101 MHz, DMSO-d6) δ 186.4, 168.2, 146.1, 143.3, 140.9, 139.7, 138.4, 
135.3, 129.1, 128.3, 126.2, 120.1. HRMS (ESI-QTOF) m/z: [M + H]+ Calcd for 
C12H9O3 201.0552; Found 201.0556. 
Methyl 1-formyl-3-iodoazulene-6-carboxylate (22). Compound 20 (0.257 g, 1.20 mmol) 
was dissolved in anhydrous DCM (3 mL) under argon. The blue solution was cooled to 0 °C 
and NIS (0.270 g, 1.20 mmol) was added. The mixture was stirred at 0 °C for 30 min, an 
additional 1.5 equiv of NIS (0.405 g, 1.80 mmol) was added, and stirring was continued at 0 
°C for 1 h and then at room temperature for 19 h. The reaction mixture was eluted through a 
pad of neutral alumina with DCM and concentrated in vacuo to give 22 as a green, amorphous 
solid (0.401 g, 98%). 1H NMR (400 MHz, acetone-d6) δ 10.38 (s, 1H), 9.60 (d, J = 10.4 Hz, 
1H), 8.63 (s, 1H), 8.61 (d, J = 10.4 Hz, 1H), 8.53–8.49 (m, 2H), 4.04 (s, 3H). 13C NMR (101 
MHz, acetone-d6) δ 186.1, 167.8, 151.7, 146.1, 141.8, 140.7, 140.4, 136.4, 130.9, 129.4, 128.9, 
78.2, 53.9. HRMS (ESI-QTOF) m/z: [M + H]+ Calcd for C13H10O3I 340.9675; Found 340.9673. 
Methyl 1-formyl-3-phenylazulene-6-carboxylate (23). A mixture of compound 22 (0.34 g, 
1.0 mmol), phenylboronic acid (0.24 g, 2.0 mmol), Pd(dppf)Cl2 (0.037 g, 0.050 mmol), BINAP 
(0.031 g, 0.050 mmol) and Cs2CO3 (1.3 g, 4.0 mmol) in anhydrous toluene (15 mL) was heated 
under microwave irradiation 110 °C for 1 h under argon. The resulting brownish green mixture 
was filtered through a small pad of Celite with DCM (20 mL) and diluted with DCM (60 mL). 
The organic phase was washed with water (50 mL), a saturated aqueous solution of NaHCO3 
(50 mL) and brine (50 mL), dried over anhydrous Na2SO4, filtered and evaporated to provide 
a green solid. The crude product was purified by flash chromatography (DCM) to give 23 as a 
green, amorphous solid (0.25 g, 88%). 1H NMR (400 MHz, CDCl3) δ 10.46 (s, 1H), 9.65 (d, J 
= 10.0 Hz, 1H), 8.74 (d, J = 10.4 Hz, 1H), 8.49 (s, 1H), 8.43 (dd, J = 10.2, 1.4 Hz, 1H), 8.30 
(dd, J = 10.4, 1.6 Hz, 1H), 7.60–7.52 (m, 4H), 7.46–7.42 (m, 1H), 4.04 (s, 3H). 13C NMR (101 
MHz, CDCl3) δ 186.6, 167.6, 144.4, 142.5, 142.1, 139.0, 136.4, 136.3, 135.5, 133.3, 129.7, 
129.1, 128.3, 127.6, 125.5, 53.56. HRMS (ESI-QTOF) m/z: [M + H]+ Calcd for 
C19H15O3 291.1021; Found 291.1026. 
1-Formyl-3-phenylazulene-6-carboxylic acid (24). Compound 23 (0.17 g, 0.60 mmol) was 
dissolved in THF (3 mL). A 2 M aqueous solution of NaOH (1.5 mL) was added to the blue 
solution and the resulting mixture was stirred at room temperature for 2 h. A 1 M aqueous 
solution of HCl (5 mL) was added to the reaction mixture on ice bath and then the mixture was 
extracted with EtOAc (50 mL). The organic phase was washed with a 1 M aqueous solution of 
HCl (2 × 25 mL) and brine (25 mL), dried over anhydrous Na2SO4, filtered and evaporated. 
The residue was washed with DCM (20 mL) and water (20 mL) and then the blue solid was 
dissolved in THF. THF was evaporated to give 24 as a green-blue, amorphous solid (0.15 g, 
92%). 1H NMR (400 MHz, DMSO-d6) δ 10.44 (s, 1H), 9.59 (d, J = 10.4 Hz, 1H), 8.82 (d, J = 
10.4 Hz, 1H), 8.61 (s, 1H), 8.40 (dd, J = 10.2, 1.4 Hz, 1H), 8.33 (dd, J = 10.6, 1.4 Hz, 1H), 
7.67–7.54 (m, 2H), 7.58–7.54 (m, 2H), 7.46–7.42 (m, 1H). 13C NMR (101 MHz, DMSO-d6) δ 
186.5, 168.0, 143.1, 141.8, 140.9, 140.3, 136.8, 135.8, 135.0, 132.1, 129.4, 129.3, 129.0, 128.7, 
127.3, 125.0. HRMS (ESI-QTOF) m/z: [M + H]+ Calcd for C18H13O3 277.0865; Found 
277.0870. 
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1-Formyl-3-phenylazulene-6-carboxamide (25). Compound 24 (0.055 g, 0.20 mmol) was 
dissolved in DMF (1 mL). The blue solution was cooled to 0 °C and EDC·HCl (0.042 g, 0.22 
mmol) and HOBt·H2O (0.034 g, 0.22 mmol) were added. The reaction mixture was stirred at 
0 °C for 15 min and at room temperature for 1 h. Aqueous NH3 (25%, 0.037 mL, 0.50 mmol) 
was added and the stirring was continued at room temperature for 3.5 h. H2O (15 mL) was 
added to the reaction mixture and it was extracted with EtOAc (30 mL). The organic phase was 
washed with a 1 M aqueous solution of HCl (15 mL) and a saturated aqueous solution of 
NaHCO3 (15 mL), dried over anhydrous Na2SO4, filtered and evaporated to provide a blue 
solid. The crude product was purified by flash chromatography (manual gradient of 
EtOAc/MeOH 1:0 → 3:1) to give 25 as a green, amorphous solid (0.019 g, 35%). 1H NMR 
(400 MHz, DMSO-d6) δ 10.45 (s, 1H), 9.58 (d, J = 10.0 Hz, 1H), 8.79 (d, J = 10.4 Hz, 1H), 
8.57 (s, 1H), 8.35 (s, 1H), 8.09 (dd, J = 10.2, 1.4 Hz, 1H), 8.04 (dd, J = 10.4, 1.6 Hz, 1H), 7.83 
(s, 1H), 7.66 (d, J = 7.6 Hz, 2H), 7.56 (t, J = 7.6 Hz, 2H), 7.44 (t, J = 7.4 Hz, 1H). 13C NMR 
(101 MHz, DMSO-d6) δ 186.6, 169.9, 146.0, 142.1, 141.1, 140.3, 137.1, 136.4, 135.1, 131.9, 
129.4, 129.0, 128.0, 127.7, 127.3, 124.9. HRMS (ESI-QTOF) m/z: [M + H]+ Calcd for 
C18H14NO2 276.1024; Found 276.1030. 
Methyl 2-(azulen-6-yl)acetate (26). 6-Methylazulene (0.71 g, 5.0 mmol) was dissolved in 
anhydrous THF (20 mL) under argon. A 1 M solution of LDA in hexane/THF (5.5 mL, 5.5 
mmol) was added to the blue solution at 0 °C. The solution turned dark red and was first stirred 
at 0 °C for 10 min and then at room temperature for 20 min. The solution was cooled to −78 
°C and methyl chloroformate (0.39 mL, 5.0 mmol) was added. The solution was stirred at −78 
°C for 10 min and then allowed to warm to 0 °C over a period of 45 min. The mixture was 
quenched with a 1 M aqueous solution of HCl (10 mL) and it was extracted with EtOAc (80 
mL). The organic phase was washed with a 1 M aqueous solution of HCl (2 × 40 mL), a 
saturated aqueous solution of NaHCO3 (2 × 40 mL) and brine (40 mL), dried over anhydrous 
Na2SO4, filtered and evaporated to provide a blue oil. The crude product was purified by flash 
chromatography (manual gradient of n-heptane/DCM 4:1 → 0:1) to give 26 as a blue, 
amorphous solid (0.52 g, 52%). 1H NMR (400 MHz, CDCl3) δ 8.29 (d, J = 10.4 Hz, 2H), 7.89 
(t, J = 3.8 Hz, 1H), 7.39 (d, J = 3.6 Hz, 2H), 7.15 (d, J = 10.4 Hz, 2H), 3.82 (s, 2H), 3.72 (s, 
3H). 13C NMR (101 MHz, CDCl3) δ 171.7, 143.6, 139.4, 137.1, 135.8, 124.5, 118.7, 52.4, 47.0. 
HRMS (ESI-QTOF) m/z: [M + H]+ Calcd for C13H13O2 201.0916; Found 201.0917. 
2-[1-[4-(Trifluoromethyl)benzoyl]azulen-6-yl]acetic acid (29). Compound 28 (0.15 g, 
0.40 mmol) was dissolved in THF (5 mL). A 0.1 M aqueous solution of NaOH (5 mL) was 
added to the red solution and the resulting mixture was stirred at room temperature for 3.5 h. 
A 1 M aqueous solution of HCl (5 mL) was added to the reaction mixture on ice bath and then 
the mixture was extracted with EtOAc (40 mL). The organic phase was washed with a 1 M 
aqueous solution of HCl (2 × 20 mL) and brine (20 mL), dried over anhydrous Na2SO4, filtered 
and evaporated to provide a red solid. The crude product was purified by flash chromatography 
(manual gradient of EtOAc/AcOH 1:0 → 99:1) to give 29 as a red, amorphous solid (0.11 g, 
78%). 1H NMR (400 MHz, CDCl3) δ 9.69 (d, J = 10.0 Hz, 1H), 8.47 (d, J = 10.0 Hz, 1H), 7.98 
(d, J = 4.4 Hz, 1H), 7.92 (d, J = 7.6 Hz, 2H), 7.76 (d, J = 8.4 Hz, 2H), 7.63 (dd, J = 9.8, 1.8, 
1H), 7.52 (dd, J = 10.2, 1.8 Hz, 1H), 7.29 (d, J = 4.0 Hz, 1H), 3.96 (s, 2H). 13C NMR (101 
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MHz, CDCl3) δ 191.6, 174.8, 146.0, 144.9, 144.5, 142.6, 141.1, 138.7, 138.1, 132.8 (q, 2JC,F = 
32.6 Hz), 131.4, 129.9, 129.7, 125.3 (q, 3JC,F = 3.8 Hz), 124.8, 124.0 (q, 
1JC,F = 273.5 Hz), 
118.7, 46.3. Compound 29 decarboxylated during the HRMS analysis and only 30 was 
detected, when 29 was ionized with ESI or APPI/APCI ion source. HRMS (ESI-QTOF) m/z: 
[M + H]+ Calcd for C19H14OF3 315.0997; Found 315.0999. 
(6-Methylazulen-1-yl)[4-(trifluoromethyl)phenyl]methanone (30). Compound 29 (0.076 
g, 0.21 mmol) was dissolved in DMF (1 mL). The red solution was cooled to 0 °C and 
EDC·HCl (0.044 g, 0.23 mmol) and HOBt·H2O (0.035 g, 0.23 mmol) were added. The reaction 
mixture was stirred at 0 °C for 15 min and at room temperature for 1 h. Aqueous NH3 (25%, 
0.040 mL, 0.53 mmol) was added and the stirring was continued at room temperature for 4 h. 
H2O (15 mL) was added to the reaction mixture and it was extracted with EtOAc (30 mL). The 
organic phase was washed with a 1 M aqueous solution of HCl (15 mL) and a saturated solution 
of NaHCO3 (15 mL), dried over anhydrous Na2SO4, filtered and evaporated to provide a purple 
solid. The crude product was purified by flash chromatography (n-heptane/EtOAc 1:3) to give 
30 as a purple, amorphous solid (0.056 g, 85%). 1H NMR (400 MHz, CDCl3) δ 9.66 (d, J = 
10.4 Hz, 1H), 8.39 (d, J = 10.4 Hz, 1H), 7.92 (d, J = 8.0 Hz, 2H), 7.89 (d, J = 4.4 Hz, 1H), 7.75 
(d, J = 8.0 Hz, 2H), 7.60 (dd, J = 10.6, 1.4 Hz, 1H), 7.48 (dd, J = 10.0, 1.2 Hz, 1H), 7.22 (d, J 
= 4.0 Hz, 1H), 2.77 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 191.5, 152.7, 144.9, 144.5, 141.3, 
140.6, 138.8, 138.1, 132.5 (q, 2JC,F = 32.6 Hz), 131.3, 130.1, 129.7, 125.2 (q, 
3JC,F = 3.8 Hz), 
124.3, 124.1 (q, 1JC,F = 273.5 Hz), 118.1, 28.3. HRMS (ESI-QTOF) m/z: [M + H]
+ Calcd for 
C19H14OF3 315.0997; Found 315.1001. 
Methyl 2-(1,3-dibenzoylazulen-6-yl)acetate (31). Compound 27 (0.061 g, 0.20 mmol) and 
benzoyl chloride (0.035 mL, 0.30 mmol) were dissolved in anhydrous DCM (1 mL) under 
argon. The reaction mixture was cooled to 0 °C and AlCl3 (0.053 g, 0.40 mmol) was added. 
The orange-red solution was stirred at 0 °C for 30 min and at room temperature for 2.5 h. An 
additional 1 equiv of AlCl3 (0.027 g, 0.20 mmol) and 1.5 equiv of benzoyl chloride (0.035 mL, 
0.30 mmol) were added, and stirring was continued at room temperature for 3 h. The reaction 
mixture was quenched by a few drops of a 1 M aqueous solution of HCl on ice bath and DCM 
(25 mL) was added. The organic phase was washed with a 1 M aqueous solution of HCl (2 × 
25 mL), a saturated solution of NaHCO3 (25 mL) and water (25 mL), dried over anhydrous 
Na2SO4, filtered and evaporated to provide red solid. The crude product was purified by flash 
chromatography (manual gradient of n-heptane/DCM 1:1 → 0:1 + DCM/EtOAc 95:5) to give 
31 as a red, amorphous solid (0.060 g, 73%). 1H NMR (400 MHz, CDCl3) δ 9.77 (d, J = 10.8 
Hz, 2H), 8.21 (s, 1H), 7.85–7.82 (m, 6H), 7.57–7.53 (m, 2H), 7.50–7.45 (m, 4H), 4.01 (s, 2H), 
3.75 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 193.0, 170.5, 149.2, 146.6, 144.2, 140.5, 140.0, 
134.0, 132.0, 129.7, 128.5, 124.4, 52.8, 46.7. HRMS (ESI-QTOF) m/z: [M + H]+ Calcd for 
C27H21O4 409.1440; Found 409.1441. 
 
4.3 Biology. Materials. Human orexin-A was from NeoMPS (Strasbourg, France), Dyngo 
4a, i.e. 3-hydroxy-N′-[(2,4,5-trihydroxyphenyl)methylidene]naphthalene-2-carbohydrazide 
from Abcam (Cambridge, UK), and [125I]-orexin-A from PerkinElmer (PerkinElmer Life and 
Analytical Sciences, Waltham, MA). Probenecid was from Sigma-Aldrich (St. Luis, MO), and 
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41 (SB-334867), i.e. N-biphenyl-2-yl-1-[[(1-methyl-1H-benzimidazol-2-yl)sulfanyl]acetyl]-L-
prolinamide and 42 (TCS-1102), i.e. N-(2-methyl-6-benzoxazolyl)-N′-1,5-naphthyridin-4-yl 
urea from Tocris Bioscience (Bristol, UK). 
Cell culture and Media. CHO-hOX1 and -hOX2 cells,[31,37] and control CHO-K1 cells (not 
expressing orexin receptors; control CHO cells), were cultured in Ham’s F12 medium 
(Gibco/Life Technologies, Paisley, UK) + supplements on plastic cell culture dishes (56 cm2 
bottom area; Greiner Bio-One GmbH, Frickenhausen, Germany) as described in Jäntti et al. 
2012.[33] For binding assay we used white and for Ca2+ measurements black clear-bottom half-
area Cellstar µClear 96-well cell culture plates (Greiner Bio-One GmbH; Frickenhausen, 
Germany) with polyethyleneimine (25 μg/mL for 1 h at 37 °C; Sigma-Aldrich, St. Louis, MO, 
USA) coating. Hepes-buffered medium (HBM; 137 mM NaCl, 5 mM KCl, 1.2 mM MgCl2, 
0.44 mM KH2PO4, 4.2 mM NaHCO3, 1 mM CaCl2, 10 mM glucose, 20 mM HEPES and 0.1% 
(w/v) stripped bovine serum albumin, and adjusted to pH 7.4 with NaOH) was used as the basic 
experimental medium. 
[125I]-Orexin-A Competition Binding. We assessed the binding of the test compounds in 
intact cells essentially as in Turku et al. 2016.[9] The cells (1.5×104 per well) were plated on 
white clear bottom half-area 96-well plates. After 24h, the culture medium was exchanged for 
HBM + 30 μM dyngo 4a ± 10 μM 42 (to determine nonspecific binding). [125I]-orexin-A / 
orexin-A mixture (at final concentration of 1 nM; 1:20) mixed with each test compound was 
added after 10 min of incubation. As controls we used dilution series of orexin-A and 41. The 
plates were incubated for 90 min at room temperature, and then the medium was removed by 
water suction and the wells were allowed to dry. After adding the scintillation cocktail (Ultima 
Gold; PerkinElmer) the plates were counted in a Wallac Microbeta Trilux microplate liquid 
scintillation counter (PerkinElmer). Each ligand was tested 3–4 times at 10 μM in 
quadruplicate. 
Ca2+ elevation. Ca2+ elevations were measured essentially as described before.[9,10] The 
cells, 1.5×104 per well, were plated on black, clear bottom half-area 96-well plates. Twenty-
four hours later, cell culture medium was removed and the cells were loaded with the loading 
solution composed of FLIPR Calcium 4 Assay Kit (Molecular Devices, Sunnyvale, CA) 
dissolved in and diluted with HBM + 1 mM probenecid, for 60 min at 37 °C. Then, the plate 
was placed in a FlexStation 3 fluorescence plate reader (Molecular Devices) and the 
intracellular Ca2+ levels were measured as fluorescence changes (excitation at 485 nm, 
emission at 525 nm) at 37 °C. Each well was measured for 150 s with 30 s of baseline before 
compound addition. For Ki measurements, the test compounds (at concentrations 1–30 µM in 
a 5-fold dilution series) were added in the wells by FlexStation as a first addition, and the plate 
was measured once as described above. Then, 30 min later, 0.3 nM orexin-A was added as a 
stimulant and the measurement was repeated. Ki measurements were conducted in 
quadruplicate 3–4 times. 
For agonist activity instead, antagonists 41 and 42 were added to wells manually, when 
applicable, and incubated for 30 min before the measurement, after which the test compounds 
were added by FlexStation, and the plate was measured only once. For potentiation studies the 
orexin-A / compound and ATP / compound mixtures were added by FlexStation as a first 
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addition, and then the plate was measured according to the agonist screen. For the agonist 
screen, the measurements were conducted in triplicate two individual times. The validation of 
the putative agonists 6, 7 and 27, and all potentiation studies were conducted in triplicate 3–4 
individual times. 
Data analysis. All data are presented as mean ± SEM. Microsoft Excel was used for data 
visualizations and analyses including curve fitting as described in Kukkonen 2016.[29] Ki 
values were calculated from the determined IC50 values using the Cheng−Prusoff equation.[38] 
Two highest concentrations (18 µM and 30 µM) were left out from the curve fitting due to the 
possibility of the nonspecific effects caused by the higher compound concentrations (e.g. 
colloidal aggregation, see below). Student’s paired two-tailed t-test was used for the statistical 
comparisons. Significances are as follows: ns (not significant), P > 0.05; *P < 0.05; **P < 
0.01; ***P < 0.001. 
 
4.4 Aggregation. Compounds 19, 22 and 32 were tested for colloidal aggregation in HBM 
using a Nepheloskan Ascent (Labsystems, Finland). Compounds 19 and 32 were tested at 
concentrations 30 µM, 10 µM and 1 µM, and showed no aggregation at any of these 
concentrations (Supporting Information Figure S8, for further verification see Supporting 
Information Figure S9). Compound 22, instead, was measured at 30 µM, 18 µM, 10 µM and 1 
µM concentrations, of which the two highest showed some aggregate formation. 
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